Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Metformin Inhibits Esophageal Squamous Cell Carcinoma Viability and Mobility in vitro through Down-regulation of Long Non-coding RNA CCAT1 and SPRY4-IT1

Version 1 : Received: 23 June 2021 / Approved: 25 June 2021 / Online: 25 June 2021 (12:41:51 CEST)

How to cite: Zhang, M.; Wang, J.; Li, Y.; Qin, L.; Fan, R.; Liu, Y.; Li, W.; Qin, Y.; Lu, P. Metformin Inhibits Esophageal Squamous Cell Carcinoma Viability and Mobility in vitro through Down-regulation of Long Non-coding RNA CCAT1 and SPRY4-IT1. Preprints 2021, 2021060624 (doi: 10.20944/preprints202106.0624.v1). Zhang, M.; Wang, J.; Li, Y.; Qin, L.; Fan, R.; Liu, Y.; Li, W.; Qin, Y.; Lu, P. Metformin Inhibits Esophageal Squamous Cell Carcinoma Viability and Mobility in vitro through Down-regulation of Long Non-coding RNA CCAT1 and SPRY4-IT1. Preprints 2021, 2021060624 (doi: 10.20944/preprints202106.0624.v1).

Abstract

Evidence indicates that the long noncoding RNAs are involved in the metformin-mediated anti-cancer processes. However, the potential effects of the long noncoding RNAs in metformin-mediated anti-tumor processes in esophageal squamous cell carcinomas (ESCC) are still elusive. This study uncovered that metformin decreases the level of long noncoding RNAs CCAT1 and SPRY4-IT1 thereby contributing to the down-regulation of c-Myc and vimentin. Also, the RNA level test of human ESCC tissue confirmed the positive correlation between CCAT1 and c-Myc. These findings demonstrated that metformin facilitated anti-cancer effects by targeting the 2 long noncoding RNAs (CCAT1 and SPRY4-IT1) and their consequential targets c-Myc and vimentin. Therefore, the CCAT1 and SPRY4-IT1 might act as novel molecular targets that mediate the anti-tumor effects in esophageal squamous cell carcinoma. This helps in predicting the treatment response of metformin in patients diagnosed with esophageal squamous cell carcinoma.

Keywords

Esophageal squamous cell carcinoma; Metformin; Long noncoding RNAs; CCAT1; SPRY4-IT1; c-Myc

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.